Skip to main content
SpringerLink
Log in

Acknowledging the Clinical Heterogeneity of Lupus Erythematosus

  • Chapter
  • First Online:
Personalized Treatment Options in Dermatology

  • 923 Accesses

Abstract

The diagnosis “Lupus erythematosus” (LE) encompasses a heterogeneous group of mostly photosensitive autoimmune diseases. LE patients may present with a broad range of clinical signs, ranging from localized skin lesions to severe systemic disease with affection of internal organ systems. This chapter provides an overview of the classification of LE, reviews the current knowledge of pathophysiology, genomics, and transcriptomics, and details different pathophysiology-based therapeutic strategies within the specific LE-subsets.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48–49:14–9.

    Article  PubMed  Google Scholar 

  2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.

    Article  CAS  PubMed  Google Scholar 

  3. Parodi A, Rebora A. ARA and EADV criteria for classification of systemic lupus erythematosus in patients with cutaneous lupus erythematosus. Dermatology. 1997;194(3):217–20.

    Article  CAS  PubMed  Google Scholar 

  4. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev. 2009;8(6):467–73.

    Article  PubMed  Google Scholar 

  6. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4(5):253–63.

    Article  CAS  PubMed  Google Scholar 

  7. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979;115(12):1409–15.

    Article  CAS  PubMed  Google Scholar 

  8. Schmitt V, Meuth AM, Amler S, Kuehn E, Haust M, Messer G, et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol. 2010;162(1):64–73.

    Article  CAS  PubMed  Google Scholar 

  9. Tomasini D, Mentzel T, Hantschke M, Cerri A, Paredes B, Rutten A, et al. Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner’s lymphocytic infiltrate of the skin and cutaneous lupus erythematosus. J Cutan Pathol. 2010;37(11):1132–9.

    Article  PubMed  Google Scholar 

  10. Wenzel J, Tuting T. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol. 2007;16(5):454–63.

    Article  CAS  PubMed  Google Scholar 

  11. Arai S, Katsuoka K. Clinical entity of Lupus erythematosus panniculitis/lupus erythematosus profundus. Autoimmun Rev. 2009;8(6):449–52.

    Article  PubMed  Google Scholar 

  12. Miyashita A, Fukushima S, Makino T, Yoshino Y, Yamashita J, Honda N, et al. Proportion of lymphocytic inflammation with CD123 positive cells in lupus erythematous profundus predict a clinical response to treatment. Acta Derm Venereol. 2014;94:563–7.

    Article  CAS  PubMed  Google Scholar 

  13. Millard LG, Rowell NR. Chilblain lupus erythematosus (Hutchinson). A clinical and laboratory study of 17 patients. Br J Dermatol. 1978;98(5):497–506.

    Article  CAS  PubMed  Google Scholar 

  14. Gunther C, Hillebrand M, Brunk J, Lee-Kirsch MA. Systemic involvement in TREX1-associated familial chilblain lupus. J Am Acad Dermatol. 2013;69(4):e179–81.

    Article  PubMed  Google Scholar 

  15. Wenzel J, Bauer R, Bieber T, Bohm I. Autoantibodies in patients with Lupus erythematosus: spectrum and frequencies. Dermatology. 2000;201(3):282–3.

    Article  CAS  PubMed  Google Scholar 

  16. Wenzel J, Brahler S, Bauer R, Bieber T, Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153(1):157–62.

    Article  CAS  PubMed  Google Scholar 

  17. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990;227(3):207–10.

    Article  CAS  PubMed  Google Scholar 

  18. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL, et al. Gene expression profiling in human autoimmunity. Immunol Rev. 2006;210:120–37.

    Article  CAS  PubMed  Google Scholar 

  20. Dall’era MC, Cardarelli PM, Preston BT, Witte A, Davis Jr JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64(12):1692–7.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Freutel S, Gaffal E, Zahn S, Bieber T, Tuting T, Wenzel J. Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus. Lupus. 2011;20(12):1300–4.

    Article  CAS  PubMed  Google Scholar 

  22. Wenzel J, Worenkamper E, Freutel S, Henze S, Haller O, Bieber T, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205(4):435–42.

    Article  CAS  PubMed  Google Scholar 

  23. Arrue I, Saiz A, Ortiz-Romero PL, Rodriguez-Peralto JL. Lupus-like reaction to interferon at the injection site: report of five cases. J Cutan Pathol. 2007;34 Suppl 1:18–21.

    Article  PubMed  Google Scholar 

  24. Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18(6):871–82.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Eloranta ML, Lovgren T, Finke D, Mathsson L, Ronnelid J, Kastner B, et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60(8):2418–27.

    Article  CAS  PubMed  Google Scholar 

  26. Arriens C, Mohan C. Systemic lupus erythematosus diagnostics in the ‘omics’ era. Int J Clin Rheumatol. 2013;8(6):671–87.

    Article  CAS  Google Scholar 

  27. Gunther C, Meurer M, Stein A, Viehweg A, Lee-Kirsch MA. Familial chilblain lupus–a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology. 2009;219(2):162–6.

    Article  CAS  PubMed  Google Scholar 

  28. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39(9):1065–7.

    Article  CAS  PubMed  Google Scholar 

  29. Lee HS, Bae SC. What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE. Lupus. 2010;19(12):1452–9.

    Article  CAS  PubMed  Google Scholar 

  30. Dey-Rao R, Smith JR, Chow S, Sinha AA. Differential gene expression analysis in CCLE lesions provides new insights regarding the genetics basis of skin vs. systemic disease. Genomics. 2014;104:144–55.

    Article  CAS  PubMed  Google Scholar 

  31. Hornung T, Ko A, Tuting T, Bieber T, Wenzel J. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2012;37(2):139–42.

    Article  CAS  PubMed  Google Scholar 

  32. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420–34.

    Article  CAS  PubMed  Google Scholar 

  33. Kast RE, Scheuerle A, Wirtz CR, Karpel-Massler G, Halatsch ME. The rationale of targeting neutrophils with dapsone during glioblastoma treatment. Anticancer Agents Med Chem. 2011;11(8):756–61.

    Article  CAS  PubMed  Google Scholar 

  34. Piette EW, Werth VP. Dapsone in the management of autoimmune bullous diseases. Immunol Allergy Clin North Am. 2012;32(2):317–22, vii.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794–804.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University Clinic Bonn, Bonn, 53105, Germany

    Joerg Wenzel MD

Authors
  1. Joerg Wenzel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joerg Wenzel MD .

Editor information

Editors and Affiliations

  1. Department of Dermatology and Allergy, Center of Translational Medicine, University of Bonn, Bonn, Germany

    Thomas Bieber

  2. St. John's Institute of Dermatology, London, United Kingdom

    Frank Nestle

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Wenzel, J. (2015). Acknowledging the Clinical Heterogeneity of Lupus Erythematosus. In: Bieber, T., Nestle, F. (eds) Personalized Treatment Options in Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45840-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45840-2_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45839-6

  • Online ISBN: 978-3-662-45840-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation